Pfizer Could Join a Rare Club Next Year With Revenue Above $100B_老虎社区_美港股上老虎

Pfizer Could Join a Rare Club Next Year With Revenue Above $100B

Barrons2021-11-24

Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink. That’s up from $41.9 billion in 2020, and the ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

119

OneZeroKing
·2021-11-24
Cool
回复
2
举报
收起
- Pinkmuffin:
  yeah
  2021-11-24
  回复
  举报
1PerCentClub
·2021-11-24
Really?
回复
1
举报
收起
- 1PerCentClub:
  Earn
  2021-11-24
  回复
  举报
- 1PerCentClub:
  Big
  2021-11-24
  回复
  举报
- 1PerCentClub:
  Big
  2021-11-24
  回复
  举报
查看更多 2 条评论
Tonica
·2021-11-24
Sure. Covid helps
回复
点赞
举报
Jazim
·2021-11-24
Good
回复
1
举报
Dorcasnoobie
·2021-11-24
[财迷]
回复
1
举报
CTigger
·2021-11-24
Hmm
回复
1
举报
收起
- JooL:
  [What]
  2021-11-24
  回复
  举报
- CTigger:
  okie
  2021-11-24
  回复
  举报
kwwh
·2021-11-24
Okay
回复
2
举报
收起
- Geoz88:
  wow
  2021-11-24
  回复
  举报
- kwwh:
  good
  2021-11-24
  回复
  举报
Wallstrtbets
·2021-11-24
Thanks to Covid19.
回复
点赞
举报
BlueDragon
·2021-11-24
With this Covid-19 situation, it is expected.
回复
5
举报
收起
- RS142:
  yes
  2021-11-24
  回复
  举报
- Galaxy121678:
  👍
  2021-11-24
  回复
  举报
- Zlin:
  Ok
  2021-11-24
  回复
  举报
查看更多 1 条评论
Tj23
·2021-11-24
Wow
回复
5
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-24 07:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156246084","market":"us","top_or_hot":-1,"title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B","media":"Barrons","content":"<div>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the ...\n\n<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">网页链接</a>\n\n</div>\n","source":"lsy1601382232898","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0>Barrons</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the ...\n\n<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","article_id":"1156246084","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","pubTimestamp":1637710539,"columns":[],"sourceInfo":{"source_id":"lsy1601382232898","name":"Barrons"},"weMediaInfo":null,"summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","collect":0,"end_time":0,"defaultTopTitle":"barrons.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞明年可能会加入一个收入超过1亿美元的罕见俱乐部","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":874990901,"gmtCreate":1637717625414,"gmtModify":1637717625414,"author":{"id":"3582709148429690","authorId":"3582709148429690","name":"OneZeroKing","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3582709148429690","idStr":"3582709148429690"},"htmlText":"Cool&nbsp;","listText":"Cool&nbsp;","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874990901","repostId":1156246084,"repostType":2,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6710008,"gmtCreate":1637768954778,"gmtModify":1637768954868,"authorId":3585481264509502,"author":{"id":3585481264509502,"idStr":"3585481264509502","authorId":3585481264509502,"name":"Pinkmuffin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874990901,"type":1,"supId":0,"prevId":0,"content":"yeah","text":"yeah","html":"yeah"}],"langContent":"CN"},{"id":874057768,"gmtCreate":1637714884834,"gmtModify":1637715365133,"author":{"id":"3574026189533561","authorId":"3574026189533561","name":"1PerCentClub","avatar":"https://static.tigerbbs.com/137535c7b4b589ca0f194fe3094266bf","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3574026189533561","idStr":"3574026189533561"},"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":1,"commentSize":15,"repostSize":0,"link":"https://laohu8.com/post/874057768","repostId":1156246084,"repostType":4,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6700233,"gmtCreate":1637715236780,"gmtModify":1637718427076,"authorId":3574026189533561,"author":{"id":3574026189533561,"idStr":"3574026189533561","authorId":3574026189533561,"name":"1PerCentClub","avatar":"https://static.tigerbbs.com/137535c7b4b589ca0f194fe3094266bf","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874057768,"type":1,"supId":0,"prevId":0,"content":"Earn","text":"Earn","html":"Earn"},{"id":6700276,"gmtCreate":1637715371930,"gmtModify":1637715371957,"authorId":3574026189533561,"author":{"id":3574026189533561,"idStr":"3574026189533561","authorId":3574026189533561,"name":"1PerCentClub","avatar":"https://static.tigerbbs.com/137535c7b4b589ca0f194fe3094266bf","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874057768,"type":1,"supId":0,"prevId":0,"content":"Big","text":"Big","html":"Big"},{"id":6700274,"gmtCreate":1637715365080,"gmtModify":1637715365106,"authorId":3574026189533561,"author":{"id":3574026189533561,"idStr":"3574026189533561","authorId":3574026189533561,"name":"1PerCentClub","avatar":"https://static.tigerbbs.com/137535c7b4b589ca0f194fe3094266bf","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874057768,"type":1,"supId":0,"prevId":0,"content":"Big","text":"Big","html":"Big"},{"id":6700269,"gmtCreate":1637715354291,"gmtModify":1637715354383,"authorId":3574026189533561,"author":{"id":3574026189533561,"idStr":"3574026189533561","authorId":3574026189533561,"name":"1PerCentClub","avatar":"https://static.tigerbbs.com/137535c7b4b589ca0f194fe3094266bf","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874057768,"type":1,"supId":0,"prevId":0,"content":"💰huat","text":"💰huat","html":"💰huat"},{"id":6700253,"gmtCreate":1637715290630,"gmtModify":1637715290655,"authorId":3574026189533561,"author":{"id":3574026189533561,"idStr":"3574026189533561","authorId":3574026189533561,"name":"1PerCentClub","avatar":"https://static.tigerbbs.com/137535c7b4b589ca0f194fe3094266bf","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874057768,"type":1,"supId":0,"prevId":0,"content":"Countries","text":"Countries","html":"Countries"}],"langContent":"CN"},{"id":874062762,"gmtCreate":1637713205602,"gmtModify":1637718746820,"author":{"id":"4093583449913140","authorId":"4093583449913140","name":"Tonica","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4093583449913140","idStr":"4093583449913140"},"htmlText":"Sure.&nbsp; Covid helps","listText":"Sure.&nbsp; Covid helps","text":"Sure. Covid helps","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874062762","repostId":1156246084,"repostType":4,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874069002,"gmtCreate":1637712795901,"gmtModify":1637712845039,"author":{"id":"4091925166419540","authorId":"4091925166419540","name":"Jazim","avatar":"https://static.tigerbbs.com/85de7ecb80758afc3288fc8bb7e5ef27","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"4091925166419540","idStr":"4091925166419540"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874069002","repostId":1156246084,"repostType":4,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874082751,"gmtCreate":1637712507561,"gmtModify":1637712507710,"author":{"id":"3568627166850888","authorId":"3568627166850888","name":"Dorcasnoobie","avatar":"https://static.tigerbbs.com/fcb2f4d29a8d87a5cbbe0eaf795e5613","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3568627166850888","idStr":"3568627166850888"},"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874082751","repostId":1156246084,"repostType":4,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874081438,"gmtCreate":1637712171174,"gmtModify":1637712171301,"author":{"id":"3582928437657110","authorId":"3582928437657110","name":"CTigger","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3582928437657110","idStr":"3582928437657110"},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874081438","repostId":1156246084,"repostType":2,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6699141,"gmtCreate":1637712400093,"gmtModify":1637712400123,"authorId":3580766516032125,"author":{"id":3580766516032125,"idStr":"3580766516032125","authorId":3580766516032125,"name":"JooL","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874081438,"type":1,"supId":0,"prevId":0,"content":"[What]","text":"[What]","html":"[What]"},{"id":6699064,"gmtCreate":1637712186128,"gmtModify":1637712186210,"authorId":3582928437657110,"author":{"id":3582928437657110,"idStr":"3582928437657110","authorId":3582928437657110,"name":"CTigger","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874081438,"type":1,"supId":0,"prevId":0,"content":"okie","text":"okie","html":"okie"}],"langContent":"CN"},{"id":874018399,"gmtCreate":1637711328793,"gmtModify":1637711328883,"author":{"id":"3555838262565974","authorId":"3555838262565974","name":"kwwh","avatar":"https://static.tigerbbs.com/537cfa6ca69686b3f03387d7bc23d203","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3555838262565974","idStr":"3555838262565974"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874018399","repostId":1156246084,"repostType":4,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6699502,"gmtCreate":1637713444529,"gmtModify":1637713444561,"authorId":3579002978614578,"author":{"id":3579002978614578,"idStr":"3579002978614578","authorId":3579002978614578,"name":"Geoz88","avatar":"https://static.tigerbbs.com/40716588ae7919100620a5b5a9c48cac","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874018399,"type":1,"supId":6698796,"prevId":0,"content":"wow","text":"wow","html":"wow"},{"id":6698796,"gmtCreate":1637711337364,"gmtModify":1637711337389,"authorId":3555838262565974,"author":{"id":3555838262565974,"idStr":"3555838262565974","authorId":3555838262565974,"name":"kwwh","avatar":"https://static.tigerbbs.com/537cfa6ca69686b3f03387d7bc23d203","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874018399,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"}],"langContent":"CN"},{"id":874035971,"gmtCreate":1637710795059,"gmtModify":1637718717896,"author":{"id":"3566244878628904","authorId":"3566244878628904","name":"Wallstrtbets","avatar":"https://static.tigerbbs.com/6c38bbee1121ea92508ad9508fa15c5e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3566244878628904","idStr":"3566244878628904"},"htmlText":"Thanks to Covid19.","listText":"Thanks to Covid19.","text":"Thanks to Covid19.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874035971","repostId":1156246084,"repostType":4,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874036556,"gmtCreate":1637710682913,"gmtModify":1637720205425,"author":{"id":"4087932884013320","authorId":"4087932884013320","name":"BlueDragon","avatar":"https://static.tigerbbs.com/431c326e19a16844e147d10866565f27","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087932884013320","idStr":"4087932884013320"},"htmlText":"With this Covid-19 situation, it is expected.","listText":"With this Covid-19 situation, it is expected.","text":"With this Covid-19 situation, it is expected.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/874036556","repostId":1156246084,"repostType":4,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6698812,"gmtCreate":1637711375910,"gmtModify":1637711375946,"authorId":3574118564601995,"author":{"id":3574118564601995,"idStr":"3574118564601995","authorId":3574118564601995,"name":"RS142","avatar":"https://static.tigerbbs.com/22d2d9b1f352da24e6ea75b557ac987a","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874036556,"type":1,"supId":0,"prevId":0,"content":"yes","text":"yes","html":"yes"},{"id":6698714,"gmtCreate":1637711137551,"gmtModify":1637711137585,"authorId":4087215268151120,"author":{"id":4087215268151120,"idStr":"4087215268151120","authorId":4087215268151120,"name":"Galaxy121678","avatar":"https://static.tigerbbs.com/b0cab941d047dcba4893f77a2987c5c6","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874036556,"type":1,"supId":6698595,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":6698695,"gmtCreate":1637711104716,"gmtModify":1637711104751,"authorId":4088047212610360,"author":{"id":4088047212610360,"idStr":"4088047212610360","authorId":4088047212610360,"name":"Zlin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874036556,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6698595,"gmtCreate":1637710932313,"gmtModify":1637710932342,"authorId":4091269729215160,"author":{"id":4091269729215160,"idStr":"4091269729215160","authorId":4091269729215160,"name":"QQChai","avatar":"https://static.tigerbbs.com/31148e862df7412ae3c07fc206cad89c","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874036556,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"},{"id":874036664,"gmtCreate":1637710679527,"gmtModify":1637710679662,"author":{"id":"3571780042589602","authorId":"3571780042589602","name":"Tj23","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3571780042589602","idStr":"3571780042589602"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874036664","repostId":1156246084,"repostType":4,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohu8.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能加入收入超过$100B的罕见俱乐部</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，受Covid-19疫苗和新型Covid-19抗病毒药物销售的推动，辉瑞明年的收入将突破1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于2020年的419亿美元和FactSet普遍估计的2021年807亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师Geoffrey Porges博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年的Covid-19药物销量将达到240亿美元，2023年将达到330亿美元。他还将辉瑞新冠疫苗明年销售额的预期从此前的230亿美元上调至300亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂跻身年收入超过1000亿美元的标准普尔500指数公司行列，其中包括沃尔玛(WMT)、亚马逊(AMZN)、苹果(APPL)和CVS Health(CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到2022年底，该公司将拥有巨额资金。Porges预计，到2022年底，辉瑞的现金和有价证券余额将达到595亿美元，假设辉瑞出售其在葛兰素史克(GSK)明年分拆的消费者医疗保健业务中的权益，则为761亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>由于761亿美元在其公司口袋里烧了一个洞，辉瑞明年将有足够的火力购买任何它想购买的东西。这可能会为投资者创造一个有趣的猜谜游戏。这也可能使大型生物技术市场升温，特别是在人们猜测诺华(NVS)在出售了价值超过200亿美元的罗氏控股(RHHBY)股份后，也在寻求大额收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，Porges将辉瑞股票的目标价从之前的48美元上调至52美元。他维持对该股的市场表现评级。辉瑞股价周一收于51.20美元，周二盘前交易中下跌0.3%。今年迄今为止，该股已上涨39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦周刊在一篇杂志专题文章中指出，辉瑞公司的Covid-19抗病毒药物的明显功效表明，该公司对自己的科学所做的赌注是一个很好的赌注，而且该股票是一项很好的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges的估计远远超出了FactSet分析师的一致预期，辉瑞报告2022年收入为815亿美元，2023年收入为660亿美元。Porges写道，他对这种名为Paxlovid的抗病毒药物的销售预测是基于2005年至2007年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>Porges写道：“默克和辉瑞已宣布2022年向美国政府供应抗病毒药物的合同，价值分别为22亿美元（310万个疗程）和52.9亿美元（1000万个疗程），我们预计未来几个月还会有更多合同。”“前两份合同足以满足2021年迄今为止诊断出的46%的新冠病例，如果投入储存，将仅覆盖4%的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已计划于11月底举行咨询委员会听证会，考虑默克(MRK)的Covid-19抗病毒药物的授权。考虑辉瑞抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":119,"commentSize":10,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}